KLISBio is a clinical-stage regenerative medicine company, specializing in developing innovative technology platforms using natural silk fibroin. Silk fibroin, a widely recognized material in medicine, is biocompatible and promotes cell proliferation, thus stimulating in-vivo tissue regeneration. KLISBio's assets under development include vascular graft, bone graft substitutes, rotator cuff repair, and the flagship product SILKBridge, a silk-based nerve repair technology, slated for commercial launch in the US. Founded in 2014, KLISBio operates in the Biotechnology, Health Care, Life Sciences, and Medical Devices industries. The company received a Grant investment on 28 February 2024.
KLISBio
Silk innovation for life sciences
Founded 2014
Italy
15 employees
Grant
Biotechnology, Health Care +2
Italy
15 employees
Grant
Biotechnology, Health Care +2
General Information
Company Name
KLISBio
Founded Year
2014
Location
Italy
Italy
Employees
15
Industries
Biotechnology, Health Care, Life Sciences +1
Funding Stage
Grant
BounceWatch is an independent company data service, not affiliated with KLISBio. To contact KLISBio, visit klis.bio.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does KLISBio compare?
A PDF of KLISBio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting KLISBio soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
Italy Market
Biotechnology
About KLISBio
Business keywords: regenerative medicine, nerve repair, vascular surgery, bone graft substitutes, orthobiologics, orthopaedics, drug release, tendon and ligament repair
Funding Rounds & Investors (6)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Grant | Undisclosed | - |
|
28 Feb 2024 |
| Convertible Note | Undisclosed | - |
|
27 Apr 2023 |
| Convertible Note | Undisclosed | - |
|
26 Nov 2021 |
| Series A | Undisclosed | - |
|
21 Apr 2016 |
| Convertible Note | Undisclosed | - |
|
11 Dec 2015 |
| Grant | Undisclosed | - |
|
01 Jul 2015 |
Latest News
View All
KLISBio Alternatives & Competitors
View All Alternatives
KLISBio vs
Kuros Biosciences
United States
Grow Bone with MagnetOs
Post-IPO Equity
221 employees
Biopharma, Biotechnology
KLISBio vs
Serica is a growth-stage medical device company focused on the development of silk-based biomaterial...
Series C
15 employees
Biotechnology, Health Care
KLISBio vs
Cerapedics Inc.
United States
Cerapedics is a global orthopedics company dedicated to redefining the path to bone repair.
192 employees
Biotechnology, Health Care
FAQ About KLISBio
Silk innovation for life sciences
KLISBio was founded in 2014.
KLISBio is headquartered in Italy.
KLISBio operates in Biotechnology, Health Care, Life Sciences and Medical Devices. Its work centres on regenerative medicine, nerve repair, vascular surgery and bone graft substitutes.
KLISBio has approximately 15 employees.
KLISBio has completed 6 funding rounds. The latest funding stage is Grant.
Top alternatives and competitors to KLISBio include Kuros Biosciences, Serica, Cerapedics Inc., OssDsign , RevBio, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
KLISBio and Kuros Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for KLISBio, https://bouncewatch.com/company/klisbio, updated 10 November 2024. When citing, please name BounceWatch and link this page.
